Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial.
Alves K, Kouassi A, Nelson J, Plested JS, Kalkeri R, Zhu M, Cloney-Clark S, Cai Z, Ahmed A, McKnight I, Mallory RM, Noriega F. Alves K, et al. Among authors: plested js. Vaccine. 2026 Feb 15;73:128164. doi: 10.1016/j.vaccine.2025.128164. Epub 2025 Dec 26. Vaccine. 2026. PMID: 41455184 Free article. Clinical Trial.
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprinting.
Kalkeri R, Zhu M, Cloney-Clark S, Parekh A, Gorinson D, Cai Z, Cai MR, Mahato S, Chau G, Babu TM, Wald A, Ramanathan P, Aurelia LC, Selva KJ, Marchese AM, Fries L, Dunkle LM, Chung AW, Plested JS. Kalkeri R, et al. Among authors: plested js. J Infect. 2025 Aug;91(2):106543. doi: 10.1016/j.jinf.2025.106543. Epub 2025 Jun 26. J Infect. 2025. PMID: 40581329 Free article.
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).
Áñez G, McGarry A, Woo W, Kotloff KL, Gay CL, Zhu M, Cloney-Clark S, Nelson J, Dunbar H, Cai MR, Cho I, Cai Z, Kalkeri R, Plested JS, Patel N, Smith K, Marchese AM, Glenn GM, Mallory RM, Dunkle LM; 2019CoVn-301 Study Investigators. Áñez G, et al. Among authors: plested js. Vaccine. 2025 Aug 13;61:127362. doi: 10.1016/j.vaccine.2025.127362. Epub 2025 Jun 5. Vaccine. 2025. PMID: 40479932 Free article. Clinical Trial.
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
Alves K, Kouassi A, Plested JS, Kalkeri R, Smith K, Kaba M, Nelson J, Zhu M, Cloney-Clark S, Cai Z, Mallory RM, Noriega F; 2019nCoV-313 Study Investigators. Alves K, et al. Among authors: plested js. Vaccine. 2025 May 10;55:127046. doi: 10.1016/j.vaccine.2025.127046. Epub 2025 Apr 2. Vaccine. 2025. PMID: 40184816 Free article. Clinical Trial.
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.
Bennett C, Chau G, Clayton E, Chu L, Alvarez J, Hidalgo AB, Palanpurwala K, Plested JS, Zhu M, Cloney-Clark S, Cai Z, Kalkeri R, Hegazy K, Smith K, Neal S, Noriega F, Mallory RM, Adelglass JM; 2019nCoV-314 Study Investigators. Bennett C, et al. Among authors: plested js. J Infect. 2025 Feb;90(2):106428. doi: 10.1016/j.jinf.2025.106428. Epub 2025 Jan 26. J Infect. 2025. PMID: 39874991 Free article. Clinical Trial.
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Alves K, Kotloff K, McClelland RS, Kouassi A, Plested JS, Kalkeri R, Zhu M, Cloney-Clark S, Cai Z, Smith K, Kaba M, Nelson J, Hammershaimb EA, Mallory RM, Noriega F; 2019nCoV-313 Study Investigators. Alves K, et al. Among authors: plested js. Lancet Infect Dis. 2025 May;25(5):585-594. doi: 10.1016/S1473-3099(24)00670-4. Epub 2025 Jan 14. Lancet Infect Dis. 2025. PMID: 39824198 Clinical Trial.
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche LF, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Joseph N, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen Jose A, Foulkes S, Ahmed K, Thombrayil A, Kalonji D, Cloney-Clark S, Zhu M, Bennett C, Albert G, Marcheschi A, Plested JS, Neal S, Chau G, Cho I, Fries L, Glenn GM, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. Among authors: plested js. Hum Vaccin Immunother. 2024 Dec 31;20(1):2425147. doi: 10.1080/21645515.2024.2425147. Epub 2024 Dec 12. Hum Vaccin Immunother. 2024. PMID: 39666396 Free PMC article. Clinical Trial.
53 results